



David Bomzer

Partner

p. 860.286.2929, ext. 1317 f. 860.286.0115

e-mail. dbomzer@cantorcolburn.com

20 Church Street, 22nd Floor, Hartford, CT 06103



David has served as both in-house and outside counsel to some of the largest and most recognizable Fortune 500 companies. In these positions, he has been responsible for developing, coordinating and executing all aspects of patent protection strategies among global teams of business and technology hubs. In addition, he has developed objectives and procedures for identifying and protecting high value technology assets, and organized and led teams of technology leaders, who assisted in coordinating enterprise-wide protection efforts. David also managed patent procurement efforts by in-house and outside counsel.

David has drafted and prosecuted patent applications in the mechanical, electro-mechanical, telecommunication arts, to name a few, and participated in various post grant reviews. David also has extensive experience in procuring design patents for his clients. He has also drafted many freedom-to-operate opinions and patentability opinions for his clients. Further, David has protected his clients' interests in litigation matters via various Examination Before Trial (EBT) proceedings, including taking and defending depositions, preparing and examining infringement claim charts, preparing Markman briefs and assisting in Markman hearings.

David enjoys lecturing about intellectual property and technical subject matter, and has participated in and chaired many industry conferences and panels. David has lectured about patents, including utility and design patents, as well as other forms of intellectual property, to clients, startups, and to other attorneys via local and regional committee activities. He taught Cyber Law at Quinnipiac University School of Law as an Adjunct Professor for several years. He also taught mechanical and aerospace engineering courses to undergraduate and graduate students at the NYU Tandon School of Engineering (formerly known as Brooklyn Polytechnic University) as an Adjunct Professor for several years.

Technologies

Aerospace & Aeronautics
Artificial Intelligence
Automotive Technology
Computer and Systems Engineering
Computer Science & Software
Electrical Engineering & Electronics
Electro-Communications
Energy
Internet & E-Commerce
Mechanical Engineering
Metallurgy & Ceramics
Semiconductor Devices & Processing Methods
Telecommunications

Practice Areas

Artificial Intelligence Practice
Computer Science Practice
Derivation Proceedings
Design Patents Practice
Due Diligence in IP Acquisitions
Ex Parte Reexaminations
Expedited Patent Examination
Foreign & PCT Patent Filing
Inter Partes Review
International



Andrew Chien

Lead Counsel IP

Siemens Healthineers

Andrew Chien is currently the Lead Counsel for Intellectual Property for Point of Care Diagnostics at Siemens Healthineers, where he regularly counsels the business on matters of IP transactions, portfolio management and enforcements. Prior to joining Siemens Healthineers, Andrew was Senior Counsel of Intellectual Property at Allergan, where he focused on collaborations, licensing and M&A related to Intellectual Property. Andrew is also an active member of the New York Intellectual Property Law Association (NYIPLA), and is a former co-chair of the IP Transactions Committee.

THOMAS J. KOWALSKI

Partner



Phone: +1 212 692 1025

TJKowalski@duanemorris.com

Duane Morris LLP

1540 Broadway

New York, NY 10036-4086

USA

Duane Morris LLP

230 Park Avenue, Suite 1130

New York, NY 10169-0079

USA

Thomas J. (Tom) Kowalski is a seasoned registered U.S. patent attorney and a partner in the firm's New York (Broadway) office. He is Chair of the Life Sciences, Pharmaceuticals, and Biotechnology Division of the firm's Intellectual Property Practice Group and is a member of the firm's Life Sciences group. His practice includes biotechnology, chemical and medical apparatus litigation/contentious matters, patent prosecution, licensing, investor due diligence, and counseling, and litigation, with extensive experience in matters of personal and personalized medicine, genetics and genetic engineering (e.g., CRISPR, TALEN/TALEN, zinc fingers, siRNA, and RNAi), plant varieties and genetically modified plants, biological inventions arising from big data/data mining/AI (including from data from massively parallel sequencing, transcriptome analyses, single cell genomics, cell signatures and the various "Seq" tools, e.g., "DropSeq," "RNASeq" and "PerturbSeq"), virology, immunology, antibodies, vaccinology, T-cell receptors, cell-based therapies such as tumor infiltrating lymphocytes, biologics, pharmaceuticals, medicinal chemistry, crystallography and small molecules,

amongst other fields of biotechnology and chemistry. Mr. Kowalski also represents his clients in procuring and enforcing trademarks and design patent rights. He obtains trademark and design patent protection domestically and worldwide, and he enforces trademark rights and defends clients accused of trademark infringement in the United States. He also actively works with clients on strategies to avoid litigation, clear out the IP underbrush that impedes passage through IP thickets, and maximize patent portfolios and investor funding.

Mr. Kowalski received an American Chemistry Society Certified B.S. in Chemistry from New York University and a J.D., with honors, from St. John's University School of Law.

In fulfilling the requirements for American Chemistry Society certification, Mr. Kowalski extensively studied graduate biochemistry, graduate inorganic chemistry, genetics, and computer science; and conducted laboratory research (a joint project amongst NYU (in the laboratory of Yorke E. Rhodes, Ph.D.), Columbia University and The NASA Goddard Institute for Space Studies (under Carl A. Gottlieb, Ph.D.)).

Also while studying at NYU, he was awarded a National Science Foundation Undergraduate Research Participant (NSF-URP) Grant and performed laboratory research at Hunter College, City University of New York (in the laboratory of Joseph J. Dannenberg, Ph.D.).

Results of this research were published in the Journal of Organic Chemistry (J. J.

Dannenberg, J. K. Barton, B. Bunch, B. J. Goldberg and T. Kowalski, "Trifluoroacetolysis of optically active 2-butyl tosylate," *J. Org. Chem.* 1983, 48, 24, 4524-4527, <https://doi.org/10.1021/jo00172a016>).

Mr. Kowalski holds a number of professional appointments and affiliations including as Chair of the American Bar Association Intellectual Property Law Section Pro Bono Committee, a faculty member of the Practising Law Institute and a Chair of *PLI's Patent Boot Camp*, a member of the editorial board of the ABA's IP publication *Landslide*, and the lead author and editor of the treatise, "*The Mechanics of Patent Claim Drafting*."

Mr. Kowalski has extensive international experience and has appeared before courts and in proceedings throughout the world, including London, England; The Hague, Netherlands; Dusseldorf, Mannheim and Munich, Germany; Vienna, Austria; Tokyo, Japan; Rio de Janeiro, Brazil; and Melbourne and Canberra, Australia.

Areas of Practice

- Intellectual Property Law
- Inter Partes Proceedings
- Appellate IP Advocacy



+1.212.588.0800
jlee@haugpartners.com

RELATED SERVICES

[Due Diligence & Investigations](#)

[FDA](#)

[Intellectual Property Litigation](#)

[Licensing & Transactions](#)

[Life Sciences Litigation](#)

[Patent Prosecution](#)

Haug Partners LLP
+1.212.588.0800
haugpartners.com

WAN CHIEH (JENNY) LEE

Partner

HIGHLIGHT

Ms. Lee combines extensive experience across all aspects of patent law with a strong ability to analyze complex technical information to provide clients with business-oriented patent strategies and insights.

OVERVIEW

Wan Chieh (Jenny) Lee is a partner in the New York office of Haug Partners. Her practice focuses on strategic counseling, procurement of worldwide patent rights, due diligence, freedom to operate, and intellectual property transactions. She routinely advises clients in the pharmaceutical, biotechnology and medical device industries regarding patentability, validity, freedom-to-operate, and regulatory exclusivity. Drawing from her extensive experience across all aspects of patent practice, Ms. Lee develops and executes patent procurement strategies that are aligned with clients' immediate and long-term business goals, including product life cycle management under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act. She leverages her strong ability to digest complex technical information with her experience in both patent procurement and litigation to provide clients with valuable transactional insights and a unique approach to negotiating intellectual property terms in agreements.

Ms. Lee's experience spans a broad range of life science technologies including antibodies, vaccines, small molecule pharmaceuticals, diagnostics, veterinary formulations, data science, biomaterials and medical devices. She also has experience with a variety of other technologies including polymers, cosmetics, industrial chemicals, manufacturing process controls, paper, and software.

During her time at MIT, Ms. Lee participated in cardiac and cartilage tissue engineering research using polymeric scaffolds, for which she earned the school's bioengineering undergraduate research award. Additionally, she researched and studied drug delivery coatings for cardiovascular stents, and served as a teaching assistant for the undergraduate polymer chemistry laboratory. Ms. Lee also worked at a major pharmaceutical company where she designed and conducted experiments related to pharmaceutical manufacturing.

SPEAKING ENGAGEMENTS+

- Speaker, NYIPLA IP Transactions Bootcamp: Patents (October 6, 2022).

- Panelist, "Chemical Patent Language Workshop – The Global Quest for Reasonable Certainty," AIPLA Spring Meeting (May 17-19, 2022).
- Panelist, "Women in IP Series – IP Due Diligence," by Women in the Legal Profession Committee of the New York City Bar Association (April 20, 2022).
- Speaker, NYIPLA IP Transactions Bootcamp: Patents (October 14, 2021).
- Speaker, "Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals," AIPLA Dicta Podcast (April 2019).
- Moderator for Panel on "Ethical Considerations in Patent Prosecution and Litigation," NYIPLA 2012 Fall One-Day Patent CLE Program (January 17, 2013).
- Co-Speaker for "FDA and USPTO Overview," ACI Hatch-Waxman Bootcamp (June 25-26, 2012).
- Moderator for Patent Litigation Panel, NYIPLA 2010 Fall One-Day Patent CLE Program (November 4, 2010)
- Moderator for Patent Prosecution Updates, NYIPLA 2008 Fall One-Day Patent CLE Program (November 7, 2008).

PUBLICATIONS+

- Lee, Wan Chieh (Jenny) and Ali Berkin, Ph.D. "[Mylan Failed to 'Immediately Envisage' the Compounds in Merck's Patent Covering Januvia.](#)" Haug Partners, 14 Oct. 2022.
- Wan Chieh (Jenny) Lee, "*Medtronic v. Mirowski*: Patentees Carry the Burden of Proving Infringement in Declaratory Judgment Actions for Non-Infringement," NYIPLA Bulletin (April/May 2014).
- Ethan Horwitz, Kenneth Sonnenfeld and Jenny Lee "Bilski and Beyond: The Impact of Bilski Decision for Biotech," BioWorld Perspectives (July 22, 2010).
- Mahmood TA, Riesle J, Li SH, Lee WC, van Blitterswijk CA, and Langer R, "Dynamic Culture of Primary Chondrocytes on Porous β -TCP and HA Scaffolds in Spinner Flasks: Effects of Pore Size and Cell Seeding Density," Key Engineering Materials Vol. 219-220, Bioceramics 14, pp 257-260 (2002).

EDUCATION+

- Massachusetts Institute of Technology (S.B., Chemical Engineering, 2002)
- Benjamin N. Cardozo School of Law, Yeshiva University (J.D., 2005)

BAR ADMISSIONS+

- New York
- U.S. District Court for the Southern District of New York
- U.S. District Court for the Eastern District of New York

- U.S. Court of Appeals for the Federal Circuit
- Registered to practice before the U.S. Patent and Trademark Office

MEMBERSHIPS+

- New York Intellectual Property Law Association, Member of Board of Directors
- New York Intellectual Property Law Educational Foundation, Director
- American Intellectual Property Law Association, Chemical Practice Committee, Chair
- Asian American Bar Association of New York
- National Asian Pacific American Bar Association
- New York City Bar Association

AWARDS+

- 2023 LCLD Fellow

LANGUAGES+

- Mandarin Chinese

HEIDI LUNASIN
Special Counsel



Phone: +1 202 776 5256

HELunasin@duanemorris.com

Duane Morris LLP
901 New York Avenue N.W., Suite 700 East
Washington, DC 20001-4795
USA

Heidi E. Lunasin leverages both in-house experience and familiarity with corporate structures and practices to enhance client communication and success with respect to all aspects of intellectual property law.

As a former corporate employee, Heidi is acutely aware of challenges that in-house counsel are facing when operating on the world stage, in particular, she understands the end-goal of intellectual property is important at the onset of strategy planning in order to efficiently direct the path of protection. Recognizing early on in the innovation process where IP rights are desired and for what purpose they are needed is key to gaining the required protection in the relevant countries.

Heidi develops patent strategies in technology fields ranging from biotech, engineering, materials, medical devices, mechanical devices, manufacturing methods including, for example, additive manufacturing, molding, and technical textiles. Over the course of her career, she has advised clients in a multitude of industries, including consumer goods, medical devices, animal health, chemical and petrochemical.

Due to her extensive experience working on clearance of products, due diligence reviews, performing comprehensive and in-depth patent searches, preparing non-infringement and invalidity opinions, and drafting and evaluating intellectual property contracts, Heidi is well-positioned to develop comprehensive IP protocols for implementation, including establishing competitive patent review and enforcement programs.

Collaborating with a variety of stakeholders responsible for innovation and/or manufacturing has reinforced Heidi's commitment to intellectual property training for all those in the innovation pipeline. Perpetually curious, Heidi loves to learn new technologies and feels quite at home with designers, researchers in the lab, and the employees at the manufacturing facilities developing new processes or improvements.

Heidi has been involved in multiple worldwide patent proceedings, working with counsel throughout the world. While working on such cases she has assisted in developing appropriate strategies to defend patents asserted in litigation before the Patent Trial and Appeal Board (PTAB) as well as Opposition proceedings in Europe, Australia, etc. Further, Heidi has worked in conjunction with counsel (both foreign and US) to develop offensive strategies throughout the world.

Prior to joining Duane Morris, Heidi served as Senior Patent Counsel for adidas AG in Herzogenaurach, Germany working on all aspects of products and development in the laboratories and factories alike. While IP Counsel at Treofan in Raunheim, Germany she routinely worked with developers at the manufacturing facility to protect and defend their intellectual property rights.

Throughout Heidi's career, she has been fortunate to operate in several industries, gaining an understanding of the issues affecting them. Before studying law, she worked for the US Army Corps of Engineers, Cyro Industries, Dell Computer, and the Third Military Academy of Korea.

Heidi is registered to practice before the United States Patent and Trademark Office and admitted to practice in New York, New Jersey, and the District of Columbia. She is a 2008 graduate of Seton Hall University School of Law. She earned an M.S. in Public Health from the University of North Carolina and a B.S. in Chemical Engineering from Rutgers University.

Areas of Practice

- Intellectual Property
- Patents
- Trademark Law
- Biotechnology



+1.212.588.0800
aroper@haugpartners.com

RELATED SERVICES

Appellate Litigation

Biotechnology
Litigation

Due Diligence &
Investigations

FDA

Hatch-Waxman
Litigation

Intellectual
Property Litigation

ITC Litigation

+1.212.588.0800
haugpartners.com

ANDREW ROPER

Partner

HIGHLIGHT

Andrew Roper's strong technical ability, combined with his talent for drawing out the right facts, turns seemingly difficult cases into straightforward cases.

OVERVIEW

Andrew Roper is a partner in Haug Partners' New York offices. The majority of his practice focuses on patent litigation. Additionally, he performs due diligences, and evaluations of IP assets. Mr. Roper also regularly works on appellate matters before the Federal Circuit.

REPRESENTATIVE CASES+

- *Takeda Pharm. Co. v. Norwich Pharms., Inc.*, 2022 U.S. Dist. LEXIS 231773, 2022 WL 17959811 (D.N.J. Dec. 27, 2022) (trial victory on all asserted claims from 9 asserted patents including claims directed to the compound, prodrug technology, salts, methods of treatment, pharmacokinetics, pharmacodynamics, water content, and formulation)
- *Astellas US LLC v. Hospira, Inc.*, No. CV 18-1675-CFC, 2022 WL 1591277 (D. Del. May 19, 2022) (finding *Curia's* API and manufacturing process do not infringe polymorph patents)
- *Takeda Pharm. Co. Ltd. v. Norwich Pharms., Inc.*, No. CV 20-8966 (SRC), 2022 WL 621041 (D.N.J. Mar. 3, 2022) ("In largest part, this is a battle of the experts, a battle which Plaintiffs clearly win.")
- *NOF Corp. v. Nektar Therapeutics*, No. IPR2019-01397, 2021 WL 3438554 (P.T.A.B. Aug. 5, 2021) (key claims to branched-PEG-maleimide polymers patentable);
- *CSL Behring GmbH v. Shire Viropharma Inc.*, No. IPR2019-00459, 2019 WL 2866004 (P.T.A.B. July 2, 2019) (institution denied on patent covering biologic treatment);

Licensing & Transactions

Life Sciences Litigation

Patent Prosecution

- *Supernus Pharms., Inc. v. TWi Pharms., Inc.*, 265 F. Supp. 3d 490, (trial victory aff'd Supernus Pharms. Inc. v. TWi Pharms. Inc, 2018 U.S. App. LEXIS 25271 (Fed. Cir. Sept. 6, 2018); §285 attorney's fees awarded based on "overwhelming" trial evidence ECF No. 420-4 (D.N.J. June 27, 2019));
- *CSL Behring v. Shire Viropharma Inc.* 2017 Pat. App. LEXIS 13304, *1-2 (P.T.A.B. December 7, 2017) (institution denied on patent covering subcutaneous biologic formulation);
- *Supernus Pharms., Inc. v. Actavis Inc.*, 2016 U.S. Dist. LEXIS 30444 (D.N.J. Mar. 9, 2016) (trial victory aff'd Supernus Pharms., Inc. v. Actavis Inc., 665 Fed. Appx. 901 (Fed. Cir. Dec. 12, 2016));
- *Shire LLC v. Amneal Pharms., LLC*, 2014 U.S. Dist. LEXIS 85369 (D.N.J. June 23, 2014) (summary judgment victory aff'd Shire, LLC v. Amneal Pharms., LLC, 802 F.3d 1301 (Fed. Cir. 2015));
- *Otter Prods., LLC v. United States*, 37 F. Supp. 3d 1306 (Ct. Int'l Trade 2014); Otter v. ITC and *Speculative Product Design*, No. 14-1480, ECF Nos. 25, 34 (Fed. Cir. 2014) (denying emergency motions to stay enforcement of US Customs and Border Protection's ITC General Exclusion Order);
- *Duramed Pharms., Inc. v. Paddock Labs., Inc.*, 715 F. Supp. 2d 552 (S.D.N.Y. 2010) (summary judgment victory aff'd Duramed Pharms., Inc. v. Paddock Labs., Inc., 2011 U.S. App. LEXIS 3384 (Fed. Cir. Feb. 17, 2011).

PUBLICATIONS+

- Roper, Andrew, and Annie Bolton. "[Apple v. Corephotonics: PTAB Decision Focused on Expert's 'Typographical Error' Rather than the Parties' Arguments Violated Administrative Procedure Act.](#)" 29 Sept. 2023.
- Dhamsania, Anjali, and Andrew Roper. "[Analyzing Nexus: Recent Federal Circuit Opinions Where Individual Patent Claim Limitations Are in the Prior Art.](#)" Haug Partners, 13 July, 2023.
- Roper, Andrew, and Conrad Stumpf. "[No Clear Error to Find Lack of Written Description for a Method of Treatment Patent Despite Separate Disclosures of the Drug, Disease, and Dose \(as Part of a Range\).](#)" Haug Partners, 29 Dec. 2021.
- Andrew Roper and Michael J. Harris. "[Standing to Appeal Post-Grant Proceedings: A Brief Review of Recent Federal Circuit Opinions.](#)" *IP Litigator*, July/August 2021, Volume 27, Number 4.

- Roper, Andrew, and Chinmay Bagwe. "[Venue in Hatch-Waxman Litigation: What Courts Decided and What Litigants Are Still Fighting Over](#)." Haug Partners, 8 Dec. 2020.
- Roper, Andrew, and Michael Harris. "[Vectura Ltd. v. GlaxoSmithKline LLC: Federal Circuit Panel Affirms Vectura's \\$90 Million Damages Award](#)." Haug Partners, 1 Dec. 2020.
- Roper, Andrew, and Ali Berkin, Ph.D. "[How Different Claim Construction Standards Can Ultimately Determine the Validity of a Patent](#)." Haug Partners, 24 Nov. 2020.

EDUCATION+

- Case Western Reserve University, (B.S.E., Chemical Engineering, 2004)
- University of Virginia School of Law, (J.D., 2007)

BAR ADMISSIONS+

- New York
- Eastern District of New York
- Southern District of New York
- United States Court of Appeals for the Federal Circuit
- Registered to practice before the U.S. Patent and Trademark Office

MEMBERSHIPS+

- New York Intellectual Property Law Association
- Federal Circuit Bar Association

+1.212.588.0800
rkurz@haugpartners.com

RELATED SERVICES

Appellate Litigation

Biotechnology
Litigation

Commercial
Litigation

Due Diligence &
Investigations

Hatch-Waxman
Litigation

Intellectual
Property Litigation

Haug Partners LLP

+1.212.588.0800
haugpartners.com
Life Sciences
Litigation

RICH KURZ

Partner

HIGHLIGHT

A skilled intellectual property attorney with an extensive technical and business background.

OVERVIEW

Richard Kurz is a partner in Haug Partners LLP's New York office. His practice primarily focuses on intellectual property counseling and litigation. His litigation experience includes numerous district court cases and appeals for innovator life sciences companies concerning biologic and pharmaceutical drug products, with allegations that include patent infringement, inventorship disputes, inequitable conduct, false advertising, breach of contract, and business torts. This experience includes both brand vs. generic litigation under the Hatch-Waxman Act and brand vs. brand cases. In addition, he assists clients with counseling, due diligence, freedom-to-operate analyses, IP/know-how/trade secrets protection, and licensing and collaboration agreements concerning intellectual property rights, including drafting and negotiating contracts. He also represents clients for patent and trademark matters in the U.S. Patent and Trademark Office. He has worked with clients in diverse industries that include pharmaceuticals, biopharmaceuticals, nutritional supplements, medical devices, software, computer systems, and materials processing. Prior to law school, he worked in industry for seventeen years in engineering and manufacturing management positions. In his spare time, he teaches a course as an adjunct professor at UNH Franklin Pierce School of Law titled "Pharmaceutical Patents – Patent Protection and Litigation in the Life Sciences Industry."

REPRESENTATIVE CASES+

- *Shire LLC v. Amneal Pharmaceuticals, LLC, Actavis Elizabeth LLC, Johnson Matthey Inc., Mylan Inc., Roxane Laboratories, Inc., Sandoz Inc.*, No. 11-3781 (D.N.J.) (consolidated)
- *Shire LLC v. Amneal Pharmaceuticals, LLC*, No. 14-1736 (Fed. Cir.)
- *Shire LLC v. Mickle*, No. 10-434 (W.D. Va.)
- *Shire LLC v. Sandoz Inc.*, No. 11-1110 (D. Colo.)
- *Shire LLC v. Teva Pharmaceuticals USA Inc.*, No. 10-329 (D. Del.)

Patent Prosecution

Trade Secret Litigation

- *Hoffmann-La Roche Inc. v. Genpharm Inc.*, No. 07-4661 (D.N.J.)
- *Hoffmann-La Roche Inc. v. Apotex Inc.*, No. 12-1270 et al. (Fed. Cir.)
- *Hoffmann-La Roche Inc. v. Apotex Inc.*, No. 13-1128 et al. (Fed. Cir.)
- *Warner Chilcott Co. LLC v. Teva Pharmaceuticals USA, Inc.*, No. 08-627 (D. Del.)
- *Warner Chilcott Co. LLC v. Teva Pharmaceuticals USA, Inc.*, No. 14-1439 (Fed. Cir.)
- *Mission Pharmacal Co. v. Virtus Pharmaceuticals, LLC*, No. 13-176 (W.D. Tex.)
- *Supernus Pharmaceuticals, Inc. v. Actavis, Inc.*, No. 14-6102 (D.N.J.)
- *Supernus Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc.*, No. 14-7272 (D.N.J.)
- *Supernus Pharmaceuticals, Inc. v. Par Pharmaceutical Cos.*, No. 15-326 (D.N.J.)
- *Bayer HealthCare LLC v. Baxalta Inc.*, No. 16-1122 (D. Del.)
- *Baxalta Inc. v. Bayer HealthCare LLC*, No. 17-1316 (D. Del.)
- *Nektar Therapeutics v. Bayer HealthCare LLC*, No. 18-1355 (D. Del.)
- *Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Ltd.*, No. 21-6964 (D.N.J.)
- *Supernus Pharmaceuticals, Inc. v. Torrent Pharmaceuticals Ltd.*, No. 21-14268 (D.N.J.)
- *Supernus Pharmaceuticals, Inc. v. Lupin Ltd.*, No. 21-1293 (D. Del.)
- *Supernus Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc.*, No. 21-17104 (D.N.J.)

PUBLICATIONS+

- Kurz, Rich, and Jacqueline Marino. "[Alice Put to the Test for Video Surveillance Systems](#)." Haug Partners, 24 March, 2023.
- Kurz, Rich, and Emily Marshall Grigas. "[Orange Book Listing of System Claims Clarified by Jazz Decision](#)." Haug Partners, 3 March 2023.
- Kurz, Rich, and Anne Bolton. "[Federal Circuit Emphasizes the Importance of Prosecution History in Resolving Ambiguous Claim Terms in *University of Massachusetts v. L'Oréal USA, Inc.*](#)" Haug Partners, 11 July, 2022.
- Rich Kurz. "[Federal Circuit Clarifies the Nexus Requirement for Objective Indicia of Nonobviousness](#)." Haug Partners, 15 March 2022.

- Kurz, Rich, and Jessica Stookey. [“Failure to Show a Reasonable Expectation of Success Dooms Obviousness Allegations.”](#) Haug Partners, 4 Jan. 2022.
- Kurz, Rich, and Anna Lukacher. [“When Sending a Cease and Desist Letter Establishes Personal Jurisdiction.”](#) Haug Partners, 19 Nov. 2021.
- Rich Kurz. [“Federal Circuit Clarifies the Willful Infringement Standard and Provides Insights on Conduct That Is Exceptional in Sri V. Cisco.”](#) Haug Partners, 26 Oct. 2021.
- Richard Kurz and Kiersten Fowler. [“‘Shall Be the Property’ Is Insufficient to Automatically Assign Title to an Invention in a Contract.”](#) *IP Litigator*, November/December 2021, Volume 27, Number 6.
- Kurz, Rich. [“Alice in 101-Derland.”](#) Haug Partners, 2 July 2021.
- Kurz, Rich, and Audrey Sparschu. [“Judgment Vacated under Rule 60\(b\)\(3\) Based on a Witness’s False Testimony.”](#) Haug Partners, 18 May 2021.
- Rich Kurz. [“Federal Circuit Finds Insufficient Evidence to Establish Standing to Appeal IPR Decisions in Apple Inc. v. Qualcomm Inc.”](#) Haug Partners, 21 Apr. 2021.
- Richard Kurz and Nisha Gera. [“Federal Circuit Affirms Invalidated Decision for Columbia University’s DNA Sequencing Patents.”](#) *IP Litigator*, July/August 2021, Volume 27, Number 4.
- Kurz, Rich, and Nisha Gera. [“Teaching Away and No Reasonable Expectation of Success Arguments Insufficient to Avoid Obviousness Affirmance by the Federal Circuit for Columbia University’s DNA Sequencing Patents.”](#) Haug Partners, 5 Mar. 2021.
- Richard Kurz and Isaac Kim. [“Objective Indicia of Nonobviousness – Considered as Part of a ‘Totality of the Evidence’ Approach or a ‘Prima Facie Framework’?”](#) *IP Litigator*, May/June 2021, Volume 27, Number 3.
- Kurz, Rich, and Chinmay Bagwe. [“Meet and Confer Requirements Added for Rule 30\(b\)\(6\) Depositions.”](#) Haug Partners, 15 Jan. 2021.

- Kurz, Rich, and Ali Berkin, Ph.D. [“USPTO Updates Indefiniteness Standard in AIA Post-Grant Proceedings to Match Those of the District Court Under Nautilus.”](#) Haug Partners, 8 Jan. 2021.
- Richard Kurz and Nisha Gera. [“‘That’s the Way the Cookie Crumbles!’ Third Circuit Court of Appeals Considers Differences Between Trade Dress and Patent Protection.”](#) *IP Litigator*, January/February 2021, Volume 27, Number 1.
- Kurz, Rich, and Bonnie Gaudette. [“Induced Infringement: The Federal Circuit Addresses the Role of Skinny Labels in the Determination of Induced Infringement for ANDA Products.”](#) Haug Partners, 15 Oct. 2020.
- Kurz, Rich, and Alexander Callo. [“Federal Circuit Reverses ‘Inherency’ Obviousness Ruling in Hatch-Waxman Lawsuit.”](#) Haug Partners LLP, Haug Partners LLP, 19 July 2017.
- Kurz, Rich, and Alexander Callo. [“PTAB Grants Motion to Amend Claims in an IPR in Valeo v. Schaeffler.”](#) Haug Partners LLP, Haug Partners LLP, 23 June 2017.
- Kurz, Rich, and Alexander Callo. [“Federal Circuit: Claims Reciting a Term of Degree Found Not Indefinite in One-E-Way.”](#) Haug Partners LLP, Haug Partners LLP, 16 June 2017.
- Kurz, Rich, and Jessica Sblendorio. [“Supreme Court Interprets BPCIA Disclosure and Notice Provisions.”](#) Haug Partners LLP, Haug Partners LLP, 13 June 2017.
- Kurz, Rich, and Jessica Sblendorio. [“Sovereign Immunity Precludes IPR Challenge to a University of Maryland Patent.”](#) Haug Partners LLP, Haug Partners LLP, 25 May 2017.
- Kurz, Rich, and Alexander Callo. [“Federal Circuit Interprets the Post-AIA On-Sale Bar.”](#) Haug Partners LLP, Haug Partners LLP, 4 May 2017.
- Kurz, Rich, and Alexander Callo. [“Calculating Lost Profits in Patent Infringement Cases.”](#) Haug Partners LLP, Haug Partners LLP, 20 Mar. 2017.

AWARDS+

- SuperLawyers New York Metro 2013-2020 Rising Stars, Intellectual Property Litigation

EDUCATION+

- Purdue University (B.S.E.E., 1990)
- Franklin Pierce Law Center (J.D., 2010) (now known as University of New Hampshire Franklin Pierce School of Law), Editor-In-Chief, IDEA: The Intellectual Property Law Review (Volume 50)

BAR ADMISSIONS+

- New York
- New Jersey
- Southern District of New York
- Eastern District of New York
- District of New Jersey
- U.S. Court of Appeals for the Federal Circuit
- Supreme Court of the United States
- Registered to practice before the U.S. Patent and Trademark Office

MEMBERSHIPS+

- American Bar Association
- Intellectual Property Owners Association
- John C. Lifland American Inn of Court
- New York City Bar Association
- New York Intellectual Property Law Association

Jennifer Mandina
University at Buffalo
Senior Contact Manager

Jennifer Mandina is a Senior Contracts Manager at the University at Buffalo. She has worked in Technology Transfer at UB for nine years with a primary focus on industry sponsored research agreements. Previously, she worked as a Technology Licensing Associate at ATCC negotiating licenses and material transfer agreements. Jennifer is currently serving as a Co-Chair on the Industry-University-Government Interface committee and served as the Chair of the Women in Licensing Committee for the Licensing Executive Society (2012-2014). She has guest lectured at the University of Rochester discussing careers in Technology Transfer and has led a webinar for Technology Transfer Tactics. Jennifer is admitted to the New York State bar and is a registered patent attorney with a Masters in Biomedical Engineering. Prior to entering a career in Technology Transfer, Jennifer worked in telecommunications litigation.



Ankur Parekh
Director & Senior IP Counsel
Raytheon Missiles & Defense

Ankur Parekh has been a practicing attorney for over 15 years. He is currently Senior IP Counsel for the Raytheon Missiles & Defense division of Raytheon Technologies Corporation. He previously worked as IP counsel for the Pratt & Whitney division of Raytheon Technologies and for Legrand, a multinational conglomerate focused on electrical infrastructure and building automation. Ankur started his legal career practicing IP litigation and IP counseling at law firms in New York City.

EUGENE GORMAKH, ESQ.

One Grand Central Place
60 East 42nd Street
Forty-Seventh Floor
New York, New York 10165
Telephone (212) 505-4135
Facsimile (212) 505-4054
eugenegormakh@rosslaw.org

Eugene Gormakh is an associate at the Law Offices of Michael S. Ross, where, for over a decade, he has concentrated his practice in representing lawyers, law firms and judges before disciplinary authorities. Mr. Gormakh has represented over a hundred lawyers and law firms in disciplinary and sanction matters in multiple state and federal jurisdictions, including many accomplished practitioners in highly complex matters involving litigation misconduct, attorney advertising, fee sharing, solicitation, conflicts of interest, escrow accounting, retention agreements, and other high risk issues.

Mr. Gormakh is an Adjunct Professor of Law at Brooklyn Law School, where he teaches Professional Responsibility. He has lectured at multiple law schools and bar associations, including the New York State Academy of Trial Lawyers; and he has authored, co-authored, and assisted in the preparation of CLE materials on legal ethics issues.

Mr. Gormakh's practice includes providing proactive guidance on the application of ethical rules to the day-to-day practice of law, and the firm regularly provides outside professional responsibility counsel to multiple AM100 law firms. As part of his practice, Mr. Gormakh also represents law firms in fee dispute matters. In addition, Mr. Gormakh has extensive experience assisting law school graduates in connection with bar admission matters and attorneys seeking reinstatement to practice law after suspension or disbarment.

Mr. Gormakh is a member of the Professional Discipline Committee of the New York City Bar Association, the Association of Professional Responsibility Lawyers, and the New York State Academy of Trial Lawyers.

Mr. Gormakh joined the Law Offices of Michael S. Ross in 2009 and earned his JD/MBA from Western New England University School of Law in 2012. While in law school, Mr. Gormakh served as a law clerk at the United States Attorney's Office for the District of Massachusetts. Mr. Gormakh is admitted to practice in New York, before the United States District Courts for the Southern and Eastern Districts of New York, and before the United States Court of Appeals for the Second Circuit.